Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
43
AMRN Quote, Financials, Valuation and Earnings
Last price:
$16.47
Seasonality move
:
1.78%
Day range:
$15.57 - $16.29
52-week range:
$7.08 - $20.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
8.49x
P/B ratio:
0.74x
Volume:
52.8K
Avg. volume:
122.1K
1-year change:
60.62%
Market cap:
$338.3M
Revenue:
$228.7M
EPS (TTM):
-$4.17
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AMRN
Amarin Corp. Plc
|
$43.1M | -- | -18% | -100% | $12.00 |
|
AKTX
Akari Therapeutics Plc
|
-- | -$0.11 | -- | -53.67% | $4.53 |
|
ALKS
Alkermes Plc
|
$356.2M | $0.39 | -11.96% | -54.31% | $43.88 |
|
DBVT
DBV Technologies SA
|
$889.9K | -$0.34 | -- | -77.25% | $20.57 |
|
EVAX
Evaxion AS
|
$2.5M | -$0.01 | -100% | -99.68% | $14.18 |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$1.1B | $5.85 | 6.25% | 106.85% | $208.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AMRN
Amarin Corp. Plc
|
$16.27 | $12.00 | $338.3M | -- | $0.00 | 0% | 8.49x |
|
AKTX
Akari Therapeutics Plc
|
$0.34 | $4.53 | $12.2M | -- | $0.00 | 0% | -- |
|
ALKS
Alkermes Plc
|
$29.53 | $43.88 | $4.9B | 14.61x | $0.00 | 0% | 3.26x |
|
DBVT
DBV Technologies SA
|
$12.99 | $20.57 | $355.4M | -- | $0.00 | 0% | -- |
|
EVAX
Evaxion AS
|
$5.10 | $14.18 | $32.2M | -- | $0.00 | 0% | 3.42x |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$167.10 | $208.50 | $10.2B | 15.09x | $0.00 | 0% | 2.45x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AMRN
Amarin Corp. Plc
|
1.45% | 2.841 | 1.98% | 2.35x |
|
AKTX
Akari Therapeutics Plc
|
8.54% | -2.620 | 6.43% | 0.16x |
|
ALKS
Alkermes Plc
|
3.97% | 0.557 | 1.45% | 3.09x |
|
DBVT
DBV Technologies SA
|
23.24% | -1.892 | 5.85% | 1.41x |
|
EVAX
Evaxion AS
|
-- | 5.637 | -- | 2.80x |
|
JAZZ
Jazz Pharmaceuticals Plc
|
57.83% | 0.150 | 67.81% | 1.24x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AMRN
Amarin Corp. Plc
|
$21.2M | -$1.7M | -17.51% | -17.79% | -3.42% | -$12.8M |
|
AKTX
Akari Therapeutics Plc
|
-- | -$2.2M | -82.46% | -92.06% | -- | -$2.1M |
|
ALKS
Alkermes Plc
|
$341.2M | $89.1M | 20.4% | 22.16% | 22.6% | $84.4M |
|
DBVT
DBV Technologies SA
|
-$4.3M | -$36.9M | -211.46% | -280.59% | -- | -$32.5M |
|
EVAX
Evaxion AS
|
-- | -$4.4M | -238.97% | -- | -54.59% | -- |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$828.9M | $161.5M | -3.78% | -9.16% | 14.34% | $429.4M |
Amarin Corp. Plc vs. Competitors
-
Which has Higher Returns AMRN or AKTX?
Akari Therapeutics Plc has a net margin of -15.58% compared to Amarin Corp. Plc's net margin of --. Amarin Corp. Plc's return on equity of -17.79% beat Akari Therapeutics Plc's return on equity of -92.06%.
Company Gross Margin Earnings Per Share Invested Capital AMRNAmarin Corp. Plc42.97% -$0.37 $465.6M AKTXAkari Therapeutics Plc-- -$0.19 $24.8M -
What do Analysts Say About AMRN or AKTX?
Amarin Corp. Plc has a consensus price target of $12.00, signalling downside risk potential of -22.73%. On the other hand Akari Therapeutics Plc has an analysts' consensus of $4.53 which suggests that it could grow by 1233.33%. Given that Akari Therapeutics Plc has higher upside potential than Amarin Corp. Plc, analysts believe Akari Therapeutics Plc is more attractive than Amarin Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings AMRNAmarin Corp. Plc0 1 1 AKTXAkari Therapeutics Plc1 0 0 -
Is AMRN or AKTX More Risky?
Amarin Corp. Plc has a beta of 0.708, which suggesting that the stock is 29.246% less volatile than S&P 500. In comparison Akari Therapeutics Plc has a beta of 0.279, suggesting its less volatile than the S&P 500 by 72.076%.
-
Which is a Better Dividend Stock AMRN or AKTX?
Amarin Corp. Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akari Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amarin Corp. Plc pays -- of its earnings as a dividend. Akari Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMRN or AKTX?
Amarin Corp. Plc quarterly revenues are $49.4M, which are larger than Akari Therapeutics Plc quarterly revenues of --. Amarin Corp. Plc's net income of -$7.7M is lower than Akari Therapeutics Plc's net income of -$6.4M. Notably, Amarin Corp. Plc's price-to-earnings ratio is -- while Akari Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp. Plc is 8.49x versus -- for Akari Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRNAmarin Corp. Plc8.49x -- $49.4M -$7.7M AKTXAkari Therapeutics Plc-- -- -- -$6.4M
-
Which has Higher Returns AMRN or ALKS?
Alkermes Plc has a net margin of -15.58% compared to Amarin Corp. Plc's net margin of 21%. Amarin Corp. Plc's return on equity of -17.79% beat Alkermes Plc's return on equity of 22.16%.
Company Gross Margin Earnings Per Share Invested Capital AMRNAmarin Corp. Plc42.97% -$0.37 $465.6M ALKSAlkermes Plc86.56% $0.49 $1.8B -
What do Analysts Say About AMRN or ALKS?
Amarin Corp. Plc has a consensus price target of $12.00, signalling downside risk potential of -22.73%. On the other hand Alkermes Plc has an analysts' consensus of $43.88 which suggests that it could grow by 48.58%. Given that Alkermes Plc has higher upside potential than Amarin Corp. Plc, analysts believe Alkermes Plc is more attractive than Amarin Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings AMRNAmarin Corp. Plc0 1 1 ALKSAlkermes Plc11 3 0 -
Is AMRN or ALKS More Risky?
Amarin Corp. Plc has a beta of 0.708, which suggesting that the stock is 29.246% less volatile than S&P 500. In comparison Alkermes Plc has a beta of 0.450, suggesting its less volatile than the S&P 500 by 55.029%.
-
Which is a Better Dividend Stock AMRN or ALKS?
Amarin Corp. Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alkermes Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amarin Corp. Plc pays -- of its earnings as a dividend. Alkermes Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMRN or ALKS?
Amarin Corp. Plc quarterly revenues are $49.4M, which are smaller than Alkermes Plc quarterly revenues of $394.2M. Amarin Corp. Plc's net income of -$7.7M is lower than Alkermes Plc's net income of $82.8M. Notably, Amarin Corp. Plc's price-to-earnings ratio is -- while Alkermes Plc's PE ratio is 14.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp. Plc is 8.49x versus 3.26x for Alkermes Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRNAmarin Corp. Plc8.49x -- $49.4M -$7.7M ALKSAlkermes Plc3.26x 14.61x $394.2M $82.8M
-
Which has Higher Returns AMRN or DBVT?
DBV Technologies SA has a net margin of -15.58% compared to Amarin Corp. Plc's net margin of --. Amarin Corp. Plc's return on equity of -17.79% beat DBV Technologies SA's return on equity of -280.59%.
Company Gross Margin Earnings Per Share Invested Capital AMRNAmarin Corp. Plc42.97% -$0.37 $465.6M DBVTDBV Technologies SA-- -$1.21 $68.9M -
What do Analysts Say About AMRN or DBVT?
Amarin Corp. Plc has a consensus price target of $12.00, signalling downside risk potential of -22.73%. On the other hand DBV Technologies SA has an analysts' consensus of $20.57 which suggests that it could grow by 58.35%. Given that DBV Technologies SA has higher upside potential than Amarin Corp. Plc, analysts believe DBV Technologies SA is more attractive than Amarin Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings AMRNAmarin Corp. Plc0 1 1 DBVTDBV Technologies SA3 0 1 -
Is AMRN or DBVT More Risky?
Amarin Corp. Plc has a beta of 0.708, which suggesting that the stock is 29.246% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.102, suggesting its less volatile than the S&P 500 by 210.179%.
-
Which is a Better Dividend Stock AMRN or DBVT?
Amarin Corp. Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amarin Corp. Plc pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMRN or DBVT?
Amarin Corp. Plc quarterly revenues are $49.4M, which are larger than DBV Technologies SA quarterly revenues of --. Amarin Corp. Plc's net income of -$7.7M is higher than DBV Technologies SA's net income of -$33M. Notably, Amarin Corp. Plc's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp. Plc is 8.49x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRNAmarin Corp. Plc8.49x -- $49.4M -$7.7M DBVTDBV Technologies SA-- -- -- -$33M
-
Which has Higher Returns AMRN or EVAX?
Evaxion AS has a net margin of -15.58% compared to Amarin Corp. Plc's net margin of -64.14%. Amarin Corp. Plc's return on equity of -17.79% beat Evaxion AS's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AMRNAmarin Corp. Plc42.97% -$0.37 $465.6M EVAXEvaxion AS-- -$1.01 $74K -
What do Analysts Say About AMRN or EVAX?
Amarin Corp. Plc has a consensus price target of $12.00, signalling downside risk potential of -22.73%. On the other hand Evaxion AS has an analysts' consensus of $14.18 which suggests that it could grow by 177.94%. Given that Evaxion AS has higher upside potential than Amarin Corp. Plc, analysts believe Evaxion AS is more attractive than Amarin Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings AMRNAmarin Corp. Plc0 1 1 EVAXEvaxion AS2 0 0 -
Is AMRN or EVAX More Risky?
Amarin Corp. Plc has a beta of 0.708, which suggesting that the stock is 29.246% less volatile than S&P 500. In comparison Evaxion AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock AMRN or EVAX?
Amarin Corp. Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evaxion AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amarin Corp. Plc pays -- of its earnings as a dividend. Evaxion AS pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMRN or EVAX?
Amarin Corp. Plc quarterly revenues are $49.4M, which are larger than Evaxion AS quarterly revenues of $37.5K. Amarin Corp. Plc's net income of -$7.7M is lower than Evaxion AS's net income of -$4.9M. Notably, Amarin Corp. Plc's price-to-earnings ratio is -- while Evaxion AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp. Plc is 8.49x versus 3.42x for Evaxion AS. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRNAmarin Corp. Plc8.49x -- $49.4M -$7.7M EVAXEvaxion AS3.42x -- $37.5K -$4.9M
-
Which has Higher Returns AMRN or JAZZ?
Jazz Pharmaceuticals Plc has a net margin of -15.58% compared to Amarin Corp. Plc's net margin of 22.33%. Amarin Corp. Plc's return on equity of -17.79% beat Jazz Pharmaceuticals Plc's return on equity of -9.16%.
Company Gross Margin Earnings Per Share Invested Capital AMRNAmarin Corp. Plc42.97% -$0.37 $465.6M JAZZJazz Pharmaceuticals Plc73.6% $4.08 $9.4B -
What do Analysts Say About AMRN or JAZZ?
Amarin Corp. Plc has a consensus price target of $12.00, signalling downside risk potential of -22.73%. On the other hand Jazz Pharmaceuticals Plc has an analysts' consensus of $208.50 which suggests that it could grow by 24.78%. Given that Jazz Pharmaceuticals Plc has higher upside potential than Amarin Corp. Plc, analysts believe Jazz Pharmaceuticals Plc is more attractive than Amarin Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings AMRNAmarin Corp. Plc0 1 1 JAZZJazz Pharmaceuticals Plc10 3 0 -
Is AMRN or JAZZ More Risky?
Amarin Corp. Plc has a beta of 0.708, which suggesting that the stock is 29.246% less volatile than S&P 500. In comparison Jazz Pharmaceuticals Plc has a beta of 0.305, suggesting its less volatile than the S&P 500 by 69.522%.
-
Which is a Better Dividend Stock AMRN or JAZZ?
Amarin Corp. Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amarin Corp. Plc pays -- of its earnings as a dividend. Jazz Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMRN or JAZZ?
Amarin Corp. Plc quarterly revenues are $49.4M, which are smaller than Jazz Pharmaceuticals Plc quarterly revenues of $1.1B. Amarin Corp. Plc's net income of -$7.7M is lower than Jazz Pharmaceuticals Plc's net income of $251.4M. Notably, Amarin Corp. Plc's price-to-earnings ratio is -- while Jazz Pharmaceuticals Plc's PE ratio is 15.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp. Plc is 8.49x versus 2.45x for Jazz Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRNAmarin Corp. Plc8.49x -- $49.4M -$7.7M JAZZJazz Pharmaceuticals Plc2.45x 15.09x $1.1B $251.4M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
64
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
